Has Haider Khadim, MD received payments from drug or device companies?

Yes. Drug and device makers reported $77,741 in general payments to Haider Khadim, MD across 680 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Haider Khadim, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Haider Khadim, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Haider Khadim, MD

Medical Oncology · Syracuse, NYNPI 1174788541

Payments from drug & device makers

$77,741in general payments, 2019–2025

Across 680 payments — averaging $114.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

GSK$31K
AstraZeneca$25K
Merck$8K
Regeneron Healthcare Solutions, Inc.$3K
E.r. Squibb & Sons, L.L.C.$1K
Novartis$702
plus $8K from 54 others

What the payments were for

Consulting fees$2,4563%
Speaking & faculty fees$59,10876%
Travel & lodging$1,7132%
Food & beverage$13,63318%
Education$8311%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
GSK	36	$31,106
AstraZeneca	74	$25,356
Merck	52	$8,358
Regeneron Healthcare Solutions, Inc.	10	$2,744
E.r. Squibb & Sons, L.L.C.	55	$1,126
Novartis	46	$702
Johnson & Johnson(2 entities)	42	$614
Pfizer	47	$608
Astellas Pharma US Inc	23	$521
Eisai Inc.	19	$496
Daiichi Sankyo Inc.	22	$474
AbbVie	16	$450
Genentech USA, Inc.	26	$400
Takeda Pharmaceuticals U.S.A., Inc.	14	$370
Puma Biotechnology, Inc.	13	$250
Incyte Corporation	9	$238
Sirtex Medical Inc	4	$204
Bristol Myers Squibb	12	$201
Acrotech Biopharma Inc.	4	$196
Genmab U.S., Inc.	4	$191
Pharmacyclics LLC, An Abbvie Company	5	$177
Amgen	11	$177
Adaptive Biotechnologies Corporation	6	$175
Lilly USA, LLC	9	$172
Bayer	8	$164
EMD Serono, Inc.	8	$149
AVEO Pharmaceuticals, Inc.	3	$148
Sanofi	7	$133
Servier Pharmaceuticals LLC	6	$128
Gilead(2 entities)	8	$120
Seagen Inc.	4	$117
Array Biopharma Inc	7	$109
Astellas Pharma Global Development	1	$102
Ipsen Biopharmaceuticals, Inc	4	$95
Rigel Pharmaceuticals, Inc.	4	$67
Exelixis Inc.	4	$60
Karyopharm Therapeutics Inc.	3	$57
Blueprint Medicines Corporation	2	$53
CTI Biopharma Corp.	2	$53
Tersera Therapeutics LLC	3	$50
Apellis Pharmaceuticals, Inc.	2	$49
Morphosys, US Inc.	3	$49
Beigene USA, Inc.	2	$45
Taiho Oncology, Inc.	3	$43
Springworks Therapeutics, Inc.	2	$42
Coherus Oncology, Inc.	2	$40
Telix Pharmaceuticals	2	$37
Pharmacosmos Therapeutics Inc.	2	$35
Azurity Pharmaceuticals, Inc.	1	$34
Myriad Genetic Laboratories, Inc.	2	$32
Clovis Oncology, Inc.	3	$32
Jazz Pharmaceuticals Inc.	2	$29
Sanofi-aventis U.S. LLC	2	$28
Grifols USA, LLC	1	$25
Boehringer Ingelheim	1	$24
Stemline Therapeutics Inc.	1	$24
Fresenius Kabi USA, LLC	1	$22
Shire North American Group Inc	1	$21
Global Blood Therapeutics, Inc.	1	$19
Spectrum Pharmaceuticals Inc.	1	$18

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

OJJAARA$30,690
IMFINZI$12,330
TAGRISSO$11,474
LYNPARZA$4,689
KEYTRUDA$2,773
LIBTAYO$2,561
LENVIMA$219
SIR-Spheres Microspheres$158
OPDIVO$125
JEMPERLI$124
Beleodaq$123
TIVDAK$113
Reblozyl$109
Enhertu$105
XTANDI$102

How this compares

$77,741 in reported general payments places this provider in the 45th percentile of 498 medical oncology providers in New York.

See all medical oncology providers in New York →

Medicare billing

Part B allowed, 2024

$54,632

Medicare patients

185

Services billed

463

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Prochlorperazine Maleate	71	$1,172
Ondansetron OdtOndansetron	46	$1,167
Anastrozole	54	$799
Dexamethasone	21	$379
LoperamideLoperamide Hcl	14	$146
Prednisone	34	$135
Hydroxyurea	17	$115
Letrozole	14	$49

Paid to pharmacies, not to this prescriber.

Other medical oncology in Syracuse

Anthony MatoIthaca$40.3M
Robert MotzerNew York$32.8M
Alan HoNew York$32M
Michael MorrisNew York$30.4M
Matthew GalskyNew York$28.1M
Wungki ParkNew York$25.5M
Komal JhaveriNew York$22.3M
Joshua RichterNew York$19.9M
Jia RuanNew York$19.8M
Andrea CercekNew York$17.8M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →